Skip to main content
Endocrinology and Metabolism logoLink to Endocrinology and Metabolism
. 2026 May 14;41(5):638–658. doi: 10.3803/EnM.2025.2660

Dietary Secoisolariciresinol Diglucoside Alleviates Polycystic Ovary Syndrome in Rats Through Inhibiting Inflammation and Modulating Gut/Vaginal Microbiota

Xiaoxia Zhang 1,*, Mei Liu 2,*, Shan Li 1, Yiwei Li 3, Junbai Ma 3, Yuanyuan Liu 3, Feng Zhang 3, Jiani Zhang 4, Ting Wang 3,✉, Hao Wang 1,✉
PMCID: PMC13748721  PMID: 42129616

Abstract

Background

Polycystic ovary syndrome (PCOS) is an endocrine–metabolic disorder characterized by hyperandrogenism, anovulation, and polycystic ovaries, and it is frequently associated with low-grade inflammation and microbiota dysbiosis. Secoisolariciresinol diglucoside (SDG), a flax-derived polyphenol, exhibits estrogenic and anti-inflammatory properties. This study explored the therapeutic potential of dietary SDG in a rat model of PCOS.

Methods

Female Sprague-Dawley rats were divided into four groups: control, model, SDG-treated control, and SDG-treated model. After 3 weeks of PCOS modeling, dietary SDG was administered for 8 weeks. Samples were collected after the intervention for subsequent analyses.

Results

SDG improved estrous cyclicity, ovulation, ovarian morphology, and sex hormone balance. It reduced obesity, dyslipidemia, insulin resistance, and oxidative stress. Inflammation was alleviated through reductions in interleukin (IL)-1β, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-α, along with an elevation in IL-10. SDG increased splenic regulatory T cells and intestinal γδT cells while reducing ovarian and peritoneal macrophages. Gut microbiota composition was reshaped, with increased abundances of Bifidobacterium, Butyrivibrio, and Ruminiclostridium, and decreased abundances of Bacteroides and Parasutterella. Vaginal microbiota composition improved, as indicated by increased Lactobacillus and decreased Enterobacteriaceae. Plasma lipopolysaccharide levels decreased, whereas short-chain fatty acids increased. Metabolomic analysis highlighted alterations in histidine metabolism.

Conclusion

SDG ameliorates PCOS by suppressing inflammation and modulating gut and vaginal microbiota.

Keywords: Polycystic ovary syndrome, Secoisolariciresinol diglucoside, Sex steroid hormones, Inflammation, Gut microbiota, Vaginal microbiota

GRAPHICAL ABSTRACT

graphic file with name enm-2025-2660f9.webp

INTRODUCTION

Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrinological disorders among women of reproductive age, with a global prevalence estimated to range between approximately 11% and 13% [1]. PCOS is commonly characterized by hyperandrogenism, anovulation, and polycystic ovarian morphology [2]. Beyond reproductive abnormalities, the majority of women with PCOS also experience metabolic dysfunction, including obesity, dyslipidemia, and insulin resistance (IR) [3]. Current therapeutic approaches for PCOS primarily aim to address endocrine abnormalities and ameliorate associated clinical symptoms. However, due to the obscure etiology and complex mechanisms underlying PCOS, there are currently no definitive preventive measures or curative treatments. Therefore, exploring novel and effective therapeutic agents for PCOS is urgently required.

It has long been postulated that sex hormone and endocrine abnormalities are major contributors to ovulatory dysfunction in PCOS [2]. Epidemiological data indicate that approximately 50% to 80% of patients with PCOS have obesity [4]. Obesity, particularly abdominal obesity, may accelerate the progression of dyslipidemia and IR associated with PCOS. Excessive insulin levels stimulate ovarian androgen secretion. These hormonal disturbances, characterized by androgen excess and gonadotropin (luteinizing hormone [LH] and follicle-stimulating hormone [FSH]) imbalance, lead to follicular developmental arrest and impaired follicular maturation [5]. This process results in the accumulation of immature follicles within the ovary and the formation of multiple cysts, ultimately producing the characteristic polycystic ovarian morphology [6]. Accordingly, correcting hormonal and metabolic disturbances may contribute to improving ovulatory dysfunction in patients with PCOS.

Numerous studies have reported that patients with PCOS exist in a state of systemic chronic low-grade inflammation [7]. Clinical investigations have demonstrated significantly elevated levels of pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α), in PCOS patients [8]. Recent evidence further suggests that aberrant activation of ovarian macrophages, along with numerical and functional deficiencies in regulatory T (Treg) cells, is closely associated with PCOS-related inflammation [9]. As key components of innate immunity, macrophages play an indispensable role in inflammatory regulation. In parallel, Treg cells are essential for maintaining immune tolerance and balancing inflammatory and regulatory responses [10]. Chronic inflammatory states may be further exacerbated by obesity and oxidative stress. Moreover, local ovarian inflammation may disrupt ovulation and contribute to the initiation or amplification of systemic inflammation. Consequently, targeting both ovarian and systemic inflammation represents a promising strategy for alleviating ovulatory dysfunction in PCOS.

Imbalances in gut and vaginal microbiota (VMB) are considered important factors in the onset and progression of PCOS [11]. Previous studies have shown that patients with PCOS exhibit reduced intestinal microbial richness and diversity [11], along with increased abundances of potentially pathogenic bacteria, including Bacteroides, Parabacteroides, Lactobacillus, Fusobacterium, and Escherichia/Shigella [12], compared with healthy controls. Consistently, mice transplanted with fecal microbiota from PCOS patients developed PCOS-like phenotypes, including IR, ovarian cyst-like follicles, and elevated testosterone (T) levels [13]. These findings indicate that alterations in intestinal microbiota can influence intestinal permeability and microbial metabolite production, thereby affecting PCOS pathogenesis. In addition, studies of VMB in PCOS have revealed significantly reduced Lactobacillus abundance, accompanied by increased Gardnerella vaginalis and Prevotella [14]. Collectively, these observations suggest that alterations in VMB diversity are also strongly associated with PCOS. Accordingly, reconstructing gut microbiota and VMB through probiotics or prebiotics may represent an innovative, efficient, and noninvasive strategy for preventing and alleviating PCOS.

With advances in precision nutrition, dietary supplements have attracted increasing interest as potential strategies for preventing and treating PCOS. Secoisolariciresinol diglucoside (SDG), a polyphenolic compound derived from flax lignans, has received widespread attention due to its multiple health-promoting effects [15]. Previous studies have demonstrated that SDG possesses anti-inflammatory and antioxidant properties, as well as cardiovascular protective and hypocholesterolemic effects [16]. In addition, as a major phytoestrogen, SDG can be metabolized by intestinal microbiota into the bioactive compounds enterodiol and enterolactone. These metabolites can subsequently bind estrogen receptors and exert estrogenic or anti-estrogenic effects [17]. However, the specific impact of dietary SDG on PCOS and its underlying mechanisms remains largely unclear.

The present study was designed to evaluate the effects of dietary SDG supplementation on inflammation and gut microbiota/VMB in a rat model of PCOS, as well as to explore the underlying mechanisms. The findings of this study may provide new insights into potential therapeutic targets for PCOS.

METHODS

Animals and diet

Six-week-old female Sprague-Dawley rats (193±10 g) were obtained from the Laboratory Animal Center of Ningxia Medical University. All animals were housed at the Laboratory Animal Center and fed a standard commercial diet. All animal experiments were conducted with the approval of the Ethics Committee of Ningxia Medical University (No. 2022-084). Letrozole was purchased from Hengrui Pharmaceutical Co. Ltd., Jiangsu, China (H19991001). SDG (purity >96.5%) was obtained from Shanghai Yuanye Biotechnology Co. Ltd., Shanghai, China (B36167).

Experimental design

A schematic representation of the animal experimental design is shown in Fig. 1A. After 1 week of acclimatization, rats were randomly assigned to four groups (n=8 rats/group): negative control group (CON), model group (MOD), SDG control group (SDG), and SDG intervention model group (MOD+SDG). The PCOS rat model was established as previously described [18]. Specifically, rats in the MOD and MOD+SDG groups received letrozole at a dose of 1 mg/kg daily for 21 consecutive days by gavage, whereas rats in the CON and SDG groups received an equivalent volume of normal saline (NS). Vaginal smears were collected to determine estrous cycle stages based on the presence and proportion of leukocytes, nucleated epithelial cells, and cornified epithelial cells. After successful model establishment, rats in the SDG and MOD+SDG groups were administered SDG at a dose of 20 mg/kg daily for 8 weeks by gavage [19], while rats in the CON and MOD groups received an equivalent volume of NS. Body weight and estrous cycles were monitored weekly and daily throughout the experimental period, respectively. After the final treatment, fecal samples and vaginal secretions were collected and immediately stored at −80°C. Subsequently, rats were euthanized, and blood and relevant tissue samples were harvested for further analyses.

Fig. 1.

Fig. 1

Secoisolariciresinol diglucoside (SDG) intervention ameliorated estrous cyclicity in polycystic ovary syndrome (PCOS) rats. (A) Schematic overview of the experimental design. (B) Wright-Giemsa staining of vaginal smears representing estrous cycle stages. (C–F) Representative estrous cycles of rats in the (C) control (CON), (D) model (MOD), (E) SDG, and (F) MOD+SDG groups. SD, Sprague-Dawley.

Wright-Giemsa staining of vaginal smears

To determine the estrous cycle phase, vaginal smears were collected daily from all rats and stained using Wright-Giemsa staining (RBR00502, Baso, Wuhan, China) [20]. The stage of the estrous cycle was confirmed by examining the proportion and morphology of cells under a light microscope. The estrous cycle consists of four phases characterized by different predominant cell types: proestrus, predominantly nucleated epithelial cells; estrus, predominantly cornified epithelial cells; metestrus, a mixture of leukocytes, nucleated epithelial cells, and cornified epithelial cells; and diestrus, predominantly leukocytes [21].

Ovary hematoxylin and eosin staining

Ovarian tissues were collected, fixed overnight in 4% paraformaldehyde, and dehydrated through an ascending ethanol gradient followed by xylene treatment. The ovaries were then paraffin- embedded, serially sectioned into 5-μm-thick sections, and stained with hematoxylin and eosin (H&E). H&E staining was performed according to the manufacturer’s instructions (G1120, Solarbio, Beijing, China). The total numbers of cystic follicles and corpora lutea were counted under light microscopy. Normal follicles were defined as follicles containing an intact oocyte and well-organized granulosa cells. Cystic follicles were identified by a large fluid-filled antral cavity, absence of an oocyte, a thin granulosa cell layer, and a thickened theca cell layer [22].

Plasma lipid metabolism detection

Biochemical indicators of lipid metabolism, including plasma total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), were determined using an AU400 automatic biochemical analyzer (Olympus, Tokyo, Japan).

IR tests

IR was evaluated using the homeostasis model assessment of insulin resistance (HOMA-IR), calculated as (fasting plasma glucose [FPG]×fasting insulin concentration [FINS])/22.5, as previously described. FPG and FINS levels (F3462-A, Fankewei Biology, Shanghai, China) were subsequently measured to assess the presence of IR.

Plasma oxidative stress determination

Plasma malondialdehyde (MDA) content and the enzymatic activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were evaluated using commercial assay kits (A003-1-2, A001-1-2, A005-1-2; Nanjing Jiancheng Bioengineering Institute, Nanjing, China), in accordance with the manufacturer’s instructions.

Enzyme-linked immunosorbent assay

Plasma sex hormones, including T, estradiol (E2), LH, FSH, progesterone (PROG), and sex hormone-binding globulin (SHBG), were measured using enzyme-linked immunosorbent assay (ELISA) kits (JL10538, JL12534, JL11706, JL13251, L15546, JL11739; Shanghai Jianglai, Shanghai, China). In addition, plasma and ovarian tissues were collected to measure inflammatory cytokines, including IL-1β, IL-6, IL-10, IL-17A, TNF-α, and monocyte chemoattractant protein-1 (MCP-1), using ELISA kits (JL20884, JL20896, JL13427, JL20880, JL13202, JL11450; Shanghai Jianglai). All sex hormone and inflammatory cytokine measurements were performed according to the manufacturer’s instructions. Each sample was analyzed in triplicate.

Isolation of mononuclear cells from peripheral blood, ovary, small intestine, spleen tissues, and peritoneal lavage fluids

Peripheral blood was collected from the orbital venous plexus of rats and centrifuged at 1,500 rpm for 10 minutes. After centrifugation, cells from the lower layer were collected and incubated with 10 mL red blood cell (RBC) lysis solution (R1010, Solarbio) for 10 minutes at 4°C to selectively lyse erythrocytes while preserving leukocytes. The cells were then centrifuged at 400 ×g for 5 minutes. Supernatants were discarded, and the cell pellets were resuspended in Roswell Park Memorial Institute (RPMI) 1640 medium. Cell concentrations were adjusted to 1× 106 cells/mL for flow cytometry (FCM) staining.

Spleen tissues were gently ground and filtered through a 200- mesh filter membrane. Following centrifugation at 400 ×g for 5 minutes, cells were collected. RBCs were lysed using RBC lysis buffer, after which cells were washed with RPMI 1640 to obtain a lymphocyte suspension. The final cell concentration was adjusted to 1×106 cells/mL.

Small intestine tissues were minced and suspended in 5 mL RPMI 1640 containing 0.05% (w/v) type IV collagenase (C5138, Sigma, St. Louis, MO, USA), followed by shaking at 150 ×g for 40 minutes at 37°C. Subsequently, the specimens were washed with RPMI 1640 containing 2% fetal bovine serum (164210-50, BI, Herzliya Pituach, Israel) and filtered through a nylon fiber column for T cell isolation. The filtered supernatants were centrifuged at 400 ×g for 7 minutes at 4°C. After removal of the supernatant, the cell pellets were resuspended in RPMI 1640 and adjusted to 1×106 cells/mL.

For ovarian tissue, follicles were punctured using a 20 mL syringe needle under an anatomical microscope and suspended in 10 mL phosphate-buffered saline (PBS) containing 0.05% (w/v) type IV collagenase at 37°C for 10 minutes. The specimens were then filtered through a 300-mesh nylon membrane. Filtered supernatants were washed with RPMI 1640 by centrifugation at 400 ×g for 5 minutes at 4°C. Cell pellets were resuspended in RPMI 1640 and adjusted to 1×106 cells/mL. For isolation of resident peritoneal macrophages, 5 mL of ice-cold PBS was injected into the peritoneal cavity of rats, and peritoneal lavage fluid was collected. The final cell concentration was adjusted to 1×106 cells/mL.

FCM analysis

For Treg cell analysis, 100 μL of single-cell suspensions from peripheral blood and spleen were incubated with 1 μL fluorescein isothiocyanate (FITC)-conjugated CD4 antibody (ab239230, Abcam, Waltham, MA, USA) for 30 minutes at 4°C. Subsequently, fixing/permeabilization solution (00-5523-00, eBioscience, San Diego, CA, USA) was added, followed by incubation for 30 minutes at 4°C in the dark and washing with wash buffer. The cells were then stained with phycoerythrin (PE)-conjugated forkhead box P3 (Foxp3) antibody (12-5773-82, eBioscience) for 30 minutes at 4°C. Isotype-matched control antibodies were used in parallel.

A 100 μL of single-cell suspensions from the small intestine and spleen were stained with 1 μL of PE-conjugated γδT-cell receptor (γδTCR) antibody (ab131596, Abcam) and FITC-conjugated CD3 antibody (201403, BioLegend, San Diego, CA, USA) for 30 minutes at 4°C in the dark. Similarly, 100 μL of single-cell suspensions from ovarian tissue and peritoneal lavage fluids were simultaneously incubated with 1 μL of PECy7-conjugated CD45 (202216, BioLegend), allophycocyanin-conjugated CD68 (ab221251, Abcam), and FITC-conjugated CD86 (200305, BioLegend) antibodies for 30 minutes at 4°C in the dark.

Immunofluorescence staining

To further evaluate the effects of SDG treatment on macrophages, immunofluorescence staining was performed to detect M1 macrophage expression in ovarian tissues. Tissue sections were dewaxed, rehydrated, and subjected to antigen retrieval by heating in sodium citrate buffer in a microwave oven at medium power for 18 minutes. The tissue sections were demarcated using an immunohistochemistry pen and blocked with goat serum at room temperature for 30 minutes. After removal of excess serum, sections were incubated overnight at 4°C in the dark with mouse anti-rat CD68 antibody (ab31630, 1:1,000 dilution, Abcam) and rabbit anti-rat inducible nitric oxide synthase (iNOS) antibody (ab213987, 1:1,000 dilution, Abcam). After washing with PBS, sections were incubated with goat anti-rabbit Cy3-conjugated secondary antibody (GB21303, 1:200 dilution, Servicebio, Wuhan, China) and goat anti-mouse Alexa Fluor®488- conjugated secondary antibody (GB25301, 1:200 dilution, Servicebio) at 37°C for 1 hour. Following PBS washes, sections were mounted using anti-fluorescence quenching medium containing 4′,6-diamidino-2-phenylindole (DAPI; S2110, Solarbio) and examined under a fluorescence microscope (BX51, Olympus). The number of positive cells per ovarian section was quantified using ImageJ software version 1.8.0 (National Institutes of Health, Bethesda, MD, USA), with observers blinded to the experimental groups.

Gut microbiota and VMB sequencing analysis

After treatment, fresh fecal samples and vaginal secretions were collected from rats for subsequent DNA extraction. Sample collection procedures were performed as previously described [23].

Bacterial DNA was extracted using the cetyltrimethylammonium bromide (CTAB) method. Briefly, appropriate amounts of lysozyme and sample were added to 1,000 μL CTAB lysis buffer, followed by incubation in a 65°C water bath with intermittent inversion to ensure complete lysis. After centrifugation, phenol (pH 8.0), chloroform, and isoamyl alcohol were added to the supernatant at a ratio of 25:24:1, mixed by inversion, and centrifuged at 12,000 ×g for 10 minutes. Chloroform and isoamyl alcohol (24:1) were then added to the recovered supernatant, followed by centrifugation under the same conditions. The resulting supernatant was mixed with isopropanol and incubated at −20°C to precipitate DNA. After centrifugation, the DNA pellet was washed twice with 1 mL of 75% ethanol and air-dried at room temperature. DNA was dissolved in double-distilled water (ddH2O). If necessary, samples were incubated at 55°C to 60°C for 10 minutes to facilitate dissolution. RNase A (1 μL) was added, followed by incubation at 37°C for 15 minutes to remove RNA. Extracted DNA was stored at −20°C until further analysis.

The V3–V4 hypervariable regions of bacterial 16S rRNA genes were amplified using Phusion High-Fidelity polymerase chain reaction (PCR) Master Mix with GC Buffer (New England Biolabs, Ipswich, MA, USA) and the following primers (5′–3′): 341F (CCTAYGGGRBGCASCAG) and 806R (GGACTACNNGGGTATCTAAT). PCR products were separated on a 2% agarose gel and purified using the GeneJET Gel Recovery Kit (Thermo Scientific, Waltham, MA, USA). Sequencing libraries were prepared using the TruSeq DNA PCR-Free Sample Preparation Kit, followed by Qubit quantification and quality assessment. Qualified libraries were sequenced on the Illumina HiSeq 2500 platform by Beijing Novogene Technology Co. Ltd. (Beijing, China).

Measurement of fecal short-chain fatty acid concentrations

Fecal short-chain fatty acid (SCFA) concentrations were measured as previously described. SCFA analysis was performed using a single quadrupole mass spectrometer (5975B MSD) coupled with a 6890N gas chromatograph (Agilent Technologies, Santa Clara, CA, USA). A mixed standard stock solution containing four SCFAs was prepared by dissolving accurately weighed standards in ether. Working standard solutions were generated by serial dilution of the mixed stock solution. Fecal samples (100 mg) were homogenized with 100 μL of 15% phosphoric acid, 100 μL of 250 μg/mL isocyanic acid solution as an internal standard, and 400 μL of ether (70 Hz for 1 minute). The homogenates were centrifuged at 12,000 ×g for 10 minutes at 4°C, and the resulting supernatants were transferred to vials for gas chromatography–mass spectrometry (GC–MS) analysis. The GC system was equipped with an Agilent HP-INNOWAX capillary column (30 m × 0.25 mm inner diameter × 0.25 μm film thickness; Agilent Technologies), and helium was used as the carrier gas at a flow rate of 1 mL/min. Samples were injected in split mode (10:1) with an injection volume of 1 μL and an injector temperature of 250°C. The ion source, interface, and quadrupole temperatures were set at 230°C, 250°C, and 250°C, respectively. The column temperature was initially set at 90°C, increased to 120°C at 10°C/min, then to 150°C at 5°C/min, and finally to 250°C at 25°C/min, where it was maintained for 2 minutes, resulting in a total run time of 15 minutes. The detector was operated in electron impact ionization mode (70 eV) using both full-scan and selected ion monitoring modes.

Detection of plasma lipopolysaccharide

Plasma lipopolysaccharide (LPS) concentrations were measured using a limulus amebocyte lysate assay kit (EC32545S, Xiamen Endotoxin Test Kit, Xiamen Bioendo Technology Co. Ltd., Xiamen, China), according to the manufacturer’s instructions.

Non-targeted metabolomics analysis

Fecal samples were subjected to untargeted metabolomics analysis as previously described [24]. Briefly, 100 mg of fecal material was accurately weighed and extracted with 400 μL of methanol– water solution (4:1, v/v). The mixture was vortexed for 30 seconds and subsequently subjected to low-temperature ultrasonication for 30 minutes (5°C, 40 kHz). The extracts were allowed to stand for 30 minutes, followed by centrifugation at 13,000 ×g for 15 minutes at 4°C. The supernatants were then collected, and differential metabolites were analyzed using liquid chromatography–mass spectrometry.

Western blot

Total protein was extracted from liver tissues obtained from each experimental group. Equal amounts of protein were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and subsequently transferred onto polyvinylidene fluoride membranes. After blocking nonspecific binding sites with 5% bovine serum albumin, the membranes were incubated overnight at 4°C with primary antibodies against phosphorylated AKT (p-AKT; Cat. No. CY6569, 1:1,000; Abways, Shanghai, China) and total AKT (Cat. No. 10176-2-AP, 1:1,000; Proteintech, Rosemont, IL, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal loading control. After washing, membranes were incubated with horseradish peroxidase–conjugated secondary antibodies (SA0000-01 and SA0000-02, 1:10,000 dilution; Proteintech) for 2 hours at room temperature. Protein bands were visualized using enhanced chemiluminescence reagents and quantified using ImageJ software version 1.8.0.

Statistical analysis

Statistical analyses were performed using GraphPad Prism version 10 (GraphPad Software Inc., San Diego, CA, USA) and SPSS version 21.0 (IBM Co., Armonk, NY, USA). All experimental data are presented as the mean±standard deviation from at least three independent experiments. One-way analysis of variance was used to compare mean values among multiple groups. Differences between two groups were assessed using the Student’s t test (two-tailed). For datasets that did not meet assumptions of normality or homogeneity of variance, appropriate nonparametric tests were applied. Spearman’s correlation analysis was conducted to evaluate associations between microbiota composition and inflammatory indicators. A P<0.05 was considered statistically significant.

RESULTS

Dietary SDG ameliorated ovarian function and sex hormonal disturbance in letrozole-induced PCOS rats

The estrous cycle reflects the ovulatory and endocrine functions of the female rat ovary. To determine the impact of SDG intervention on ovarian function in PCOS rats, estrous cycle stages were assessed using vaginal smear Wright-Giemsa staining. According to established criteria, the estrous cycle of normal rats lasts 4 to 5 days and comprises proestrus, estrus, metestrus, and diestrus. As shown in Fig. 1B, during proestrus, vaginal exfoliated cells were mainly composed of nucleated epithelial cells; during estrus, cells consisted predominantly of cornified epithelial cells; during metestrus, cells comprised a mixed population of leukocytes, nucleated epithelial cells, and cornified epithelial cells; and during diestrus, cells were predominantly leukocytes. We observed that rats in the CON and SDG groups exhibited relatively stable and regular estrous cyclicity (Fig. 1C, E). However, after 17 days of letrozole administration, rats in the MOD and MOD+SDG groups remained in continuous diestrus (Fig. 1D, F), indicating disruption of the estrous cycle. Notably, following SDG supplementation, the disturbed estrous cycle gradually recovered (Fig. 1F). These results demonstrate that SDG treatment could ameliorate letrozole-induced estrous cycle disorders to a certain extent.

Subsequently, H&E staining was performed to examine ovarian anatomy and morphology. Under light microscopy, ovaries from rats in the CON and SDG groups were well developed, with follicles visible at all developmental stages, and exhibited increased numbers of corpora lutea and mature large follicles (Fig. 2A). In contrast, compared with the CON group, ovaries from the MOD group displayed marked structural disruption, characterized by an increased number of cystically dilated follicles and a reduced number of corpora lutea and corona radiata within follicles (P<0.05) (Fig. 2B, C), indicating impaired folliculogenesis. Conversely, SDG supplementation promoted the formation of corpora lutea and reduced cystic follicle dilation (P<0.05) (Fig. 2B, C). Moreover, mature follicles and follicles at various developmental stages were clearly observed, demonstrating that SDG intervention enhanced ovarian morphology and function.

Fig. 2.

Fig. 2

Secoisolariciresinol diglucoside (SDG) intervention improved ovarian morphology and function in rats with polycystic ovary syndrome (PCOS). (A) Representative hematoxylin and eosin (H&E) staining of ovarian tissue. (B, C) Quantification of corpora lutea and cystic follicles. (D–J) Plasma levels of testosterone (T), estradiol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH), LH/FSH ratio, progesterone (PROG), and sex hormone-binding globulin (SHBG). Data are expressed as mean±standard deviation. CON, control; MOD, model; L, corpora lutea; TCL, theca cell layer; GCL, granulosa cell layer; ns, not significant. aP<0.05; bP<0.01.

In addition, plasma levels of sex steroid hormones, including T, E2, LH, FSH, PROG, and SHBG, were measured. Compared with the CON group, plasma levels of T, FSH, and the LH/FSH ratio were significantly elevated in the MOD group, whereas E2, PROG, and SHBG levels were markedly reduced (P<0.05) (Fig. 2D-J), indicating severe sex hormone imbalance consistent with impaired folliculogenesis. In contrast, dietary SDG intervention significantly reversed these abnormalities by increasing E2, PROG, and SHBG levels and decreasing T, LH, and the LH/FSH ratio (P<0.05) (Fig. 2D-J). These findings confirmed the successful establishment of the PCOS model. Collectively, dietary SDG, as a potential therapeutic strategy, significantly ameliorated ovarian dysfunction and sex hormone disturbances in letrozole-induced PCOS rats.

Dietary SDG intervention alleviated obesity, dyslipidemia, IR, and oxidative stress in letrozole-induced PCOS rats

To evaluate the metabolic effects of SDG in PCOS, physiological indices including body weight, blood lipid profiles, glucose metabolism, IR, and oxidative stress were examined. Initial body weights showed no significant differences among groups. However, beginning at week 4 of intervention, a significant increase in body weight was observed in the MOD group, which persisted until the end of the experiment (P<0.05) (Fig. 3A, B). Notably, SDG administration significantly reduced body weight during the final 2 weeks compared with the MOD group (P< 0.05) (Fig. 3A, B). Similarly, plasma levels of TC, TG, and LDL-C were significantly increased, whereas HDL-C levels were decreased in the MOD group compared with the CON group (P<0.05) (Fig. 3C–F), indicating obesity-associated dyslipidemia in letrozole-induced PCOS rats. In contrast, SDG intervention markedly improved lipid metabolism by reducing TC, TG, and LDL-C levels and increasing HDL-C levels (P< 0.05) (Fig. 3C–F). Furthermore, dietary SDG treatment significantly reversed elevated FPG, FINS, and HOMA-IR values (P<0.05) (Fig. 3G–I), demonstrating improved glucose metabolism and insulin sensitivity. In addition, SDG supplementation significantly alleviated oxidative stress by reducing MDA levels and increasing total SOD and GSH-Px activities (P<0.05) (Fig. 3J–L). Collectively, these findings indicate that dietary SDG effectively mitigated obesity, dyslipidemia, IR, and oxidative stress in letrozole-induced PCOS rats.

Fig. 3.

Fig. 3

Secoisolariciresinol diglucoside (SDG) intervention alleviated obesity, dyslipidemia, insulin resistance, and oxidative stress in rats with polycystic ovary syndrome (PCOS). (A, B) Body weight growth curves and final body weights. (C–F) Plasma lipid profiles, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). (G–I) Fasting plasma glucose (FPG), fasting insulin (FINS), and homeostasis model assessment of insulin resistance (HOMA-IR) index. (J– L) Plasma malondialdehyde (MDA), total superoxide dismutase (T-SOD), and glutathione peroxidase (GSH-Px) levels. Data are expressed as mean±standard deviation. CON, control; MOD, model. aP<0.05, bP<0.01, and cP<0.001; dP<0.05, eP<0.01 vs. CON; fP<0.05 vs. MOD.

Reduced plasma and ovarian inflammation was observed in association with dietary SDG treatment in rats with PCOS

Given the critical role of immune-mediated inflammation in PCOS pathogenesis, we further assessed the anti-inflammatory effects of SDG. Plasma and ovarian levels of pro-inflammatory cytokines, including IL-1β, IL-6, IL-17A, MCP-1, and TNF-α, were significantly elevated in the MOD group compared with the CON group, whereas plasma levels of the anti-inflammatory cytokine IL-10 were significantly reduced (P<0.05) (Fig. 4). In contrast, SDG intervention markedly reversed plasma levels of IL-1β, TNF-α, MCP-1, and IL-10 compared with the MOD group (P<0.05) (Fig. 4A–F). Similarly, ovarian levels of IL-1β, IL-6, TNF-α, and MCP-1 were significantly decreased following SDG treatment (P<0.05) (Fig. 4G–L). These results indicate that dietary SDG administration may suppress chronic low-grade inflammation in PCOS by inhibiting pro-inflammatory cytokine production while enhancing anti-inflammatory responses.

Fig. 4.

Fig. 4

Secoisolariciresinol diglucoside (SDG) intervention reduced inflammatory cytokines in rats with polycystic ovary syndrome (PCOS). Enzyme-linked immunosorbent assay (ELISA) kits were used to determine plasma concentrations of (A) interleukin (IL)-1β, (B) IL-6, (C) tumor necrosis factor-α (TNF-α), (D) IL-17A, (E) monocyte chemoattractant protein-1 (MCP-1), and (F) IL-10, and ovarian tissue levels of (G) IL-1β, (H) IL-6, (I) TNF-α, (J) IL-17A, (K) MCP-1, and (L) IL-10. Data are expressed as mean±standard deviation. CON, control; MOD, model; ns, not significant. aP<0.05; bP<0.01.

Changes in inflammatory cell populations were observed in response to dietary SDG treatment in rats with PCOS

To gain insight into the mechanisms underlying the anti-inflammatory effects of SDG in PCOS rats, we examined inflammatory cell populations, including Treg cells, γδT cells, and macrophages, using FCM. As shown in Fig. 5A, B, Treg cells were identified by co-expression of CD4 and Foxp3. We found that the proportions of Treg cells in the MOD group were significantly lower than those in the CON group in both peripheral blood and spleen (P<0.05) (Fig. 5A–D). However, SDG intervention led to a significant increase in Treg cells in the spleen only (P<0.05) (Fig. 5D). Further, we examined the proportions of γδT cells, which were labeled with CD3 and γδTCR (Fig. 5E, F). The results showed that γδT cell proportions in the spleen and small intestine of the MOD group were significantly reduced compared with those in the CON group (P<0.05) (Fig. 5E–H). Nevertheless, SDG administration significantly increased the proportion of intestinal γδT cells compared with the MOD group (P<0.05) (Fig. 5F–H).

Fig. 5.

Fig. 5

Immunomodulatory effects of secoisolariciresinol diglucoside (SDG) on immune cell subsets in polycystic ovary syndrome (PCOS) rats. (A, B) Representative flow cytometry plots of peripheral blood and spleen. (C, D) Proportions of CD4+ forkhead box P3 (Foxp3)+ regulatory T cells in blood and spleen. (E, F) Representative flow cytometry plots of γδT cells in spleen and small intestine. (G, H) Proportions of CD3+ γδT-cell receptor (γδTCR)+ cells in spleen and intestine. (I) Representative flow cytometry plots of macrophages. (J, K) Proportions of CD45+CD68+ macrophages (Mψs) and CD45+CD68+CD86+ M1 macrophages. (L, M) Representative immunofluorescence staining and quantification of CD68+ inducible nitric oxide synthase (iNOS)+ M1 macrophages in ovarian tissue (scale bar=100 μm). Data are expressed as mean±standard deviation. CON, control; MOD, model; PE, phycoerythrin; FITC, fluorescein isothiocyanate; APC, allophycocyanin; ns, not significant; SSC-A, side scatter area; PC7, phycoerythrin-cyanine 7; DAPI, 4′,6-diamidino-2-phenylindole. aP<0.05; bP<0.01; cP<0.001.

Additionally, given the critical role of macrophages in inflammatory regulation, we examined macrophage populations in the ovary and peritoneal lavage fluid. Macrophages were identified by CD45 and CD68 expression, and CD45+CD68+CD86+ cells were defined as M1 macrophages (Fig. 5I, Supplemental Fig. S1A). Compared with the CON group, both total macrophages and M1 macrophages were significantly increased in the MOD group in both ovarian tissue and peritoneal lavage fluid (P< 0.05) (Fig. 5J, K, Supplemental Fig. S1B, C). Notably, SDG treatment markedly reduced the proportions of total macrophages and M1 macrophages compared with the MOD group (P<0.05) (Fig. 5J, K, Supplemental Fig. S1B, C). Consistently, double-labeling immunofluorescence staining demonstrated that the fluorescence intensity of ovarian CD68+iNOS+ (M1 macrophages) was significantly enhanced in the MOD group and attenuated in the MOD+SDG group (P<0.05) (Fig. 5L, M).

Collectively, these results indicate that the anti-inflammatory effects of SDG may primarily depend on inhibition of M1 macrophage polarization. In addition, modulation of Treg and γδT cell populations may partially contribute to the anti-inflammatory effects of SDG intervention in PCOS.

Dietary SDG intake was correlated with improved gut microbiota profiles in rats with PCOS

Dysbiosis of the intestinal microbiota has been reported to be closely associated with the development of PCOS [11]. To further clarify the impact of SDG intervention on gut microbiota composition in PCOS rats, we analyzed microbial diversity and composition in fecal samples using 16S rRNA sequencing. Venn diagram analysis revealed 636 core operational taxonomic units (OTUs) shared among all groups, while the numbers of unique OTUs in the CON, MOD, SDG, and MOD+SDG groups were 83, 11, 33, and 52, respectively (Supplemental Fig. S2A). Rank-abundance curves illustrated species richness and evenness across groups (Supplemental Fig. S2B). Subsequently, β-diversity analysis was performed using principal coordinates analysis (PCoA) and non-metric multidimensional scaling (NMDS). Both PCoA and NMDS revealed clear separation of microbial community structures among groups (Supplemental Fig. S2C, D), indicating that the gut microbiota composition in the MOD group was markedly different from that in the CON and MOD+SDG groups.

We further examined the relative abundance of gut microbiota at the phylum and genus levels. At the phylum level, Firmicutes, Bacteroidetes, and unidentified bacteria were the predominant taxa across groups (Fig. 6A), and no marked differences were observed in overall phylum composition. However, the Fir-micutes-to-Bacteroidetes (F/B) ratio was significantly increased in the MOD group compared with the CON group (P<0.05) (Fig. 6C), whereas SDG treatment significantly reduced the F/B ratio compared with the MOD group (P<0.05) (Fig. 6C). At the genus level, the overall gut microbial community structure differed among the four groups (Fig. 6B). Specifically, the relative abundances of Bacteroides and Parasutterella were significantly increased in the MOD group, whereas Bifidobacterium, Butyrivibrio, and Ruminiclostridium were significantly decreased compared with the CON group (P<0.05) (Fig. 6D–H). Notably, these alterations were significantly reversed by SDG administration (P<0.05) (Fig. 6D–H). These findings indicate that dietary SDG effectively improved gut microbiota dysbiosis in PCOS rats.

Fig. 6.

Fig. 6

Secoisolariciresinol diglucoside (SDG) intervention was associated with altered microbiota composition and microbial metabolite profiles in polycystic ovary syndrome rats. (A, B) Relative abundance of gut microbiota at the phylum and genus levels. (C) Firmicutes-to-Bacteroidetes (F/B) ratio. (D–H) Relative abundance of Bacteroides, Parasutterella, Bifidobacterium, Butyrivibrio, and Ruminiclostridium. (I, J) Relative abundance of vaginal microbiota at the phylum and genus levels. (K–M) Relative abundance of Enterobacteriaceae, Lactobacillus, and Streptococcus. (N) Plasma lipopolysaccharide (LPS) levels. (O) Representative total ion chromatogram of fecal samples. (P–R) Fecal concentrations of acetic acid, propionic acid, and butyric acid. Data are expressed as mean±standard deviation. CON, control; MOD, model; ns, not significant; EU, endotoxin unit. aP<0.05; bP<0.01; cP<0.001.

Dietary SDG modulated VMB composition in rats with PCOS

Given the potential association between VMB and PCOS [25], we further analyzed VMB composition using 16S rRNA sequencing. Venn diagram analysis showed that 675 core OTUs were shared among all groups, while the numbers of unique OTUs in the CON, MOD, SDG, and MOD+SDG groups were 568, 103, 606, and 375, respectively (Supplemental Fig. S3A). Rank-abundance curves indicated reduced richness and diversity in the MOD group compared with other groups (Supplemental Fig. S3B). Consistently, PCoA and NMDS analyses demonstrated clear separation between VMB samples from the MOD group and those from the CON and MOD+SDG groups (Supplemental Fig. S3C, D), suggesting VMB dysbiosis in PCOS rats.

At the phylum and genus levels, significant differences in VMB composition were observed among groups (Fig. 6I, J). Compared with the CON group, the relative abundances of Enterobacteriaceae and Streptococcus were significantly increased, whereas Lachnospiraceae abundance was decreased in the MOD group (P<0.05) (Fig. 6K–M). Notably, dietary SDG administration significantly reduced Enterobacteriaceae abundance and increased Lactobacillus abundance compared with the MOD group (P< 0.05) (Fig. 6K, L). These results indicate that dietary SDG ameliorated abnormal VMB composition in PCOS rats by increasing beneficial Lactobacillus and decreasing potentially pathogenic taxa.

Dietary SDG attenuated plasma LPS and increased fecal SCFAs in rats with PCOS

To further explore the association between microbial metabolites and PCOS, plasma LPS levels and fecal SCFAs were analyzed. Plasma LPS concentrations were significantly elevated in letrozole-treated rats compared with the CON group (P<0.05) (Fig. 6N). In contrast, dietary SDG administration significantly reduced plasma LPS levels compared with the MOD group (P< 0.05) (Fig. 6N), suggesting that SDG may improve intestinal barrier function in PCOS. Fecal SCFA concentrations were determined using GC–MS. As shown in the total ion chromatogram (Fig. 6O), each SCFA exhibited a distinct single peak, indicating reliable analytical performance. The concentrations of acetic acid, propionic acid, and butyric acid were significantly reduced in the MOD group compared with the CON group (P< 0.05) (Fig. 6P–R). Notably, SDG intervention significantly increased the levels of these SCFAs compared with the MOD group (P<0.05) (Fig. 6P–R). In contrast, no significant differences were observed in the concentrations of isobutyric acid, isovaleric acid, valeric acid, or caproic acid among groups (P> 0.05). Collectively, these results indicate that dietary SDG modulated microbial metabolite profiles by regulating gut and VMB.

Correlation analysis revealed complex interactions among gut/VMB, fecal SCFAs, inflammatory cytokines, and sex hormones in PCOS rats

Spearman correlation analysis revealed that the gut F/B ratio was positively correlated with pro-inflammatory cytokines and T levels, and negatively correlated with SCFAs, SHBG, PROG, and E2 levels. Butyrivibrio abundance was associated with reduced inflammation and improved hormone profiles, whereas Parasutterella abundance showed positive correlations with LPS, pro-inflammatory cytokines, T, and LH, and negative correlations with IL-10 and SCFAs. In VMB, Proteobacteria abundance was associated with pro-inflammatory and hormone-disruptive profiles, whereas Lactobacillus abundance was negatively correlated with LPS and T and positively correlated with IL-10, SCFAs, SHBG, and PROG (P<0.05) (Fig. 7). These findings support a regulatory role of microbiota in PCOS pathophysiology.

Fig. 7.

Fig. 7

Correlation between microbiota and inflammatory indicators. Spearman correlation analysis was performed. Data are expressed as mean±standard deviation. T, testosterone; E2, estradiol; LH, luteinizing hormone; PROG, progesterone; SHBG, sex hormone-binding globulin; IL, interleukin; TNF-α, tumor necrosis factor-α; MCP-1, monocyte chemoattractant protein-1; LPS, lipopolysaccharide. aP<0.05; bP<0.01; cP<0.001.

Dietary SDG intake was correlated with alterations in histidine metabolism that may contribute to the improvement of PCOS in rats

To further elucidate the molecular mechanisms by which SDG ameliorates gut microbiota dysregulation in PCOS, we performed untargeted fecal metabolomics to identify key metabolites and metabolic pathways. Metabolites were identified and analyzed using principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA). Both PCA and PLS-DA demonstrated clear group separation among the CON, MOD, and MOD+SDG groups (Fig. 8A, B). Notably, the CON and MOD+SDG groups clustered more closely, whereas the MOD group was clearly separated, indicating pronounced metabolic alterations in the PCOS model (Fig. 8A, B). Further metabolite classification revealed nine major metabolite categories, with amino acids representing the largest group (Fig. 8C).

Fig. 8.

Fig. 8

Fecal non-targeted metabolomic analysis. (A) Principal component analysis (PCA). (B) Partial least squares-discriminant analysis (PLS-DA). (C) Classification of metabolites among different groups. (D) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of differential metabolites, where larger circles indicate a greater number of enriched metabolites and redder colors indicate higher statistical significance. (E) Histidine metabolism pathway, with red circles representing metabolites and green squares representing metabolic enzymes. (F, G) Protein expression levels in liver tissue. Data are expressed as mean±standard deviation. CON, control; MOD, model; SDG, secoisolariciresinol diglucoside; p-AKT, phosphorylated AKT; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PC, principal component. aP<0.05.

Furthermore, compared with the CON group, the MOD group exhibited downregulation of 15 metabolites, including tryptamine, hyaluronic acid, cytidine, L-arginine, homovanillic acid, robustic acid, trehalose, L-phenylalanine, 3-(3-hydroxyphenyl) propanoic acid, L-gulonolactone, Pro–Lys, sinapic acid, 1-methylnicotinamide, L-homoserine, and L-acetylcarnitine, as well as upregulation of eight metabolites, including xanthurenic acid, pyridoxal, indole-3-carboxylic acid, L-tryptophan, L-isoleucine, 4-acetamidobutanoic acid, papaverine, and L-alanine (P<0.05) (Supplemental Fig. S4). Compared with the MOD group, dietary SDG administration resulted in downregulation of seven metabolites, including 4-acetamidobutanoic acid, diethylthiophosphate, indole-3-carboxylic acid, L-isoleucine, L-tryptophan, papaverine, and pomiferin, and upregulation of six metabolites, including cytidine, hyaluronic acid, r-1-methanandamide phosphate, trans-cinnamic acid, trehalose, and tryptamine (P<0.05) (Supplemental Fig. S5). An advanced bubble chart illustrated the top 18 enriched metabolic pathways based on differential fecal metabolites (Fig. 8D), in which larger circles represent a greater number of enriched metabolites and redder colors indicate higher statistical significance. Notably, differential metabolites among the three groups were predominantly enriched in the histidine metabolism pathway (Fig. 8D, E), suggesting this pathway as a potential target through which SDG may improve PCOS. Previous studies have demonstrated that histidine metabolism is closely associated with inflammation and IR [26,27]. Accordingly, we examined key proteins involved in insulin-related inflammatory signaling, including AKT and p-AKT. The results showed that p-AKT protein levels were significantly reduced in the MOD group, whereas SDG intervention markedly increased p-AKT levels (P<0.05) (Fig. 8F, G). Collectively, these findings suggest that SDG treatment may improve insulin sensitivity in PCOS rats by enhancing AKT phosphorylation.

DISCUSSION

PCOS is a complex endocrine and metabolic disorder with an incompletely understood etiology and limited therapeutic options [25]. Consequently, novel alternative therapeutic approaches are urgently needed. SDG, a major phytoestrogen in the Western diet, has long been used to treat a wide range of conditions without significant adverse effects [28]. Accordingly, the present study aimed to evaluate the effects of SDG intervention on ovarian function, inflammation, and gut/VMB in a rat model of PCOS. Our results demonstrated that dietary SDG was associated with improvements in hormonal and metabolic disturbances, enhanced follicular development, and normalization of ovulation in PCOS rats. These beneficial effects may be mediated through inhibition of macrophage-associated immune inflammation and modulation of gut and VMB. In addition, the underlying mechanisms may involve alterations in histidine metabolism. Taken together, these findings suggest that SDG may serve as an inexpensive, safe, effective, and novel adjuvant therapeutic strategy for PCOS.

Numerous studies have demonstrated that the letrozole-induced PCOS rat model closely mimics key pathophysiological features of clinical PCOS [29], and has therefore been widely used in PCOS research. Consistent with previous reports, the present study showed that letrozole-induced PCOS rats exhibited continuous diestrus, abnormal ovarian development, reduced numbers of healthy follicles and corpora lutea, and increased cystic follicles, confirming successful model establishment. Notably, SDG administration reversed these pathological alterations, indicating a beneficial effect of SDG on ovulatory function. However, despite the apparent improvement in follicular development following SDG treatment, the precise mechanisms underlying this effect remain incompletely understood.

Sex hormone imbalance is widely recognized as a primary contributor to ovulatory dysfunction in PCOS [2,29]. Elevated androgen levels and an increased LH/FSH ratio can disrupt normal follicular development and inhibit ovulation, ultimately leading to polycystic ovarian morphology [30]. In the present study, dietary SDG was associated with reduced levels of T, LH, and the LH/FSH ratio, along with increased levels of E2, PROG, and SHBG, suggesting a potential role for SDG in improving ovulatory function through modulation of sex hormone homeostasis in PCOS rats. Supporting this interpretation, a recent study reported that SDG alleviated ovariectomy-induced osteoporosis by increasing E2 levels and reducing estrogen receptor α and β expression [17], highlighting the estrogenic activity of SDG. Estrogen is known to stimulate hepatic SHBG production, thereby reducing the bioavailability of circulating androgens [31]. Therefore, it is reasonable to speculate that the inhibitory effects of dietary SDG on androgen excess and LH/FSH imbalance may be largely attributable to its phytoestrogenic properties.

In addition to endocrine dysfunction, metabolic disturbances play a critical role in PCOS-associated ovulatory impairment [32]. Hyperinsulinemia can enhance androgen synthesis in ovarian stromal cells, further exacerbating hormonal imbalance [33]. In line with previous studies [30,34], we observed that letrozoleinduced PCOS rats exhibited pronounced metabolic abnormalities, including obesity, hyperlipidemia, IR, and oxidative stress. SDG has been reported to exert lipid-lowering effects, with 12- week supplementation reducing body weight, serum lipid levels, and lipid synthesis-related gene expression in high-fat–fed mice [35]. Similarly, our findings demonstrated that SDG administration ameliorated obesity and dyslipidemia in letrozole-induced PCOS rats, potentially involving the endoplasmic reticulum stress–Ca2+–mitochondria-associated pathway [35]. Moreover, SDG treatment improved glucose metabolism and insulin sensitivity, effects that may be secondary to improved lipid homeostasis [36]. Notably, SDG also significantly attenuated oxidative stress. Previous animal studies have shown that SDG can alleviate trans-fatty-acid–induced oxidative damage by activating the nuclear factor erythroid-2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway [37], supporting its therapeutic potential in PCOS-associated oxidative injury.

Recent studies have shown that chronic low-grade inflammation is closely associated with the progression of ovarian and metabolic dysfunction in PCOS [7,38]. Elevated levels of circulating pro-inflammatory cytokines can induce peripheral IR [39], thereby promoting hyperandrogenism and ovulatory dysfunction. In addition, inflammation represents a downstream consequence of oxidative stress and can form a self-amplifying inflammatory–oxidative cascade, exacerbating ovarian tissue damage [40]. Accordingly, suppression of inflammation represents a plausible therapeutic strategy for PCOS. In the present study, dietary SDG significantly attenuated systemic and ovarian inflammation by reducing pro-inflammatory cytokines, including IL-1β, IL-6, MCP-1, and TNF-α, while increasing the anti-inflammatory cytokine IL-10. These findings are consistent with previous reports demonstrating the anti-inflammatory properties of SDG [41]. Furthermore, we investigated immune cell populations potentially involved in mediating these effects. SDG increased the proportions of splenic Treg cells and intestinal γδT cells but did not significantly affect peripheral blood Tregs or splenic γδT cells, suggesting tissue-specific immunomodulatory effects. In contrast, changes in macrophage populations were particularly pronounced. SDG significantly reduced both total macrophages and pro-inflammatory M1 macrophages in ovarian tissue and peritoneal lavage fluid, indicating that inhibition of macrophage-driven inflammation may be a primary mechanism underlying the anti-inflammatory effects of SDG. Notably, reduced M1 macrophage infiltration in the ovarian corpus luteum following SDG treatment may contribute to improved ovarian function. These findings are supported by previous studies showing that SDG suppresses NOD-like receptor family pyrin domain containing 1 (NLRP1) inflammasome activation in dextran sulfate sodium (DSS)-induced colitis and RAW264.7 macrophages [42]. However, the precise molecular mechanisms by which SDG regulates macrophage-mediated inflammation remain to be fully elucidated and may involve pathways such as Nrf2/nuclear factor κB (NF-κB) signaling [43]. Importantly, no in vitro functional assays (e.g., macrophage polarization assays, Treg or γδT suppressive function assays, or receptor-binding studies) were performed in the present study to directly validate the immunomodulatory and estrogenic effects of SDG. Such mechanistic investigations will be essential in future studies to clarify the immune- and receptor-mediated pathways underlying the protective effects of SDG in PCOS.

In recent years, an increasing number of studies have supported the notion that gut microbiota plays an important role in the occurrence and development of PCOS [11,44]. Clinical evidence has demonstrated marked differences in intestinal microbiota composition between PCOS patients and healthy individuals [11], indicating significant microbial dysbiosis in PCOS, which is consistent with the findings of the present study. We observed increased abundances of Bacteroides, Parasutterella, and an elevated F/B ratio, along with a significant reduction in Bifidobacterium, Butyrivibrio, and Ruminiclostridium in PCOS model rats. A recent study identified Bacteroides vulgatus as a representative contributor to PCOS pathogenesis [45], which is consistent with the findings of the present study. Parasutterella is typically present at low abundance in healthy individuals and is primarily involved in regulating energy metabolism and insulin sensitivity [46]. Notably, both Bacteroides and Parasutterella are Gram-negative bacteria capable of producing LPS, thereby promoting multisystemic inflammation. Consistent with this, plasma LPS levels were markedly increased in the model group, which may further impair intestinal barrier function and enhance intestinal permeability. As previously reported, the F/B ratio is strongly associated with obesity and host lipid metabolism [47]. In the present study, the increased F/B ratio observed in PCOS rats was consistent with concurrent obesity and hyperlipidemia, whereas dietary SDG reduced the F/B ratio, which may contribute to the alleviation of metabolic dysfunction. Bifidobacterium, as a well-recognized probiotic, inhibits pathogenic microorganisms and helps maintain intestinal microbial balance. Moreover, Bifidobacterium, Butyrivibrio, and Ruminiclostridium are major producers of SCFAs, which are essential for gut health and epithelial homeostasis through their anti-inflammatory properties [48]. We therefore hypothesize that intestinal microbial dysbiosis in PCOS, accompanied by reduced SCFA production, contributes to ovarian inflammation. Notably, SDG administration increased the relative abundance of Bifidobacterium, Butyrivibrio, and Ruminiclostridium, consistent with elevated levels of SCFAs, including acetic acid, propionic acid, and butyric acid. Collectively, these findings suggest that SDG ameliorates intestinal dysbiosis and multisystemic inflammation primarily by up-regulating beneficial bacteria and suppressing potentially pathogenic taxa. In addition, other microbial metabolites may also be involved. To further identify potential differential metabolites following SDG intervention, untargeted metabolomics was performed, revealing that altered metabolites were predominantly enriched in the histidine metabolism pathway, which may represent a potential mechanistic target of SDG treatment. These findings require further validation. Therefore, although our results demonstrate a strong association between SDG-mediated microbiota modulation and improvement of PCOS phenotypes, additional mechanistic evidence is needed to establish a definitive causal relationship. Importantly, these microbiota-related observations remain largely correlative, as no causal experiments— such as fecal microbiota transplantation, antibiotic-mediated depletion, or germ-free animal models—were conducted to directly demonstrate microbiota-mediated effects of SDG. Incorporation of such approaches in future studies would substantially strengthen the mechanistic link between SDG, microbial restructuring, and host metabolic and reproductive outcomes.

The VMB establishes a homeostatic and mutualistic relationship with the host and plays a critical role in reproductive health and disease [49]. Comparative analyses of VMB between healthy women and women with PCOS have shown that the relative abundance of Lactobacillus is reduced in PCOS, whereas Gardnerella and Prevotella are increased [49]. Lactobacillus is well recognized for maintaining vaginal homeostasis by producing hydrogen peroxide and lactic acid, thereby creating a protective microenvironment that limits pathogen colonization [50]. Consistent with previous research [49], the present study also confirmed a reduction in Lactobacillus in PCOS rats. Notably, we also observed a significant increase in Enterobacteriaceae and Streptococcus, which are regarded as potentially pathogenic vaginal taxa, suggesting a pronounced disruption of VMB homeostasis. Previous studies have reported that VMB composition is closely associated with sex hormone levels and TG [49], indicating that VMB dysregulation may influence ovulatory function in PCOS. Encouragingly, dietary SDG administration increased Lactobacillus abundance and reduced Enterobacteriaceae levels, suggesting that SDG contributes to restoration of vaginal microbial balance and reproductive health. However, the mechanisms underlying SDG-mediated VMB modulation remain unclear. It is uncertain whether these alterations arise secondary to systemic hormonal changes or through the local action of microbial metabolites. In addition, this study did not assess vaginal pH, local estrogen receptor expression, or SCFA concentrations, all of which could provide mechanistic insight into vaginal microenvironment regulation. Future studies integrating hormonal profiling and vaginal metabolomic analyses are therefore warranted.

Recent evidence indicates that microbial metabolites derived from histidine catabolism, such as imidazole propionate (ImP), play a critical role in IR. ImP has been shown to inhibit AKT phosphorylation and activate the p62–mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, thereby impairing insulin signaling and metabolic homeostasis [25]. In addition, ImP interferes with AMP-activated protein kinase (AMPK) activation, reducing responsiveness to metformin [26]. These findings suggest that histidine metabolism may represent a key mechanistic link between gut microbiota dysbiosis and insulin signaling dysfunction. In this context, the regulatory effects of SDG on microbial composition and histidine metabolism observed in the present study may contribute to improved insulin sensitivity and ovarian function. To directly test this hypothesis, our ongoing research will involve fecal microbiota transplantation and targeted modulation of microbial histidine metabolites to validate the causal relationship between SDG, gut microbiota, and insulin signaling pathways.

The present study demonstrates, for the first time, that dietary SDG administration may ameliorate ovarian dysfunction, suppress inflammatory responses, and modulate gut and VMB in a rat model of PCOS. These findings contribute to a deeper understanding of PCOS pathogenesis and highlight the potential of SDG as a complementary dietary strategy for PCOS management.

Footnotes

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (Grant Nos. 82460793, 82160691), the Key Research and Development Program of Ningxia, China (Grant No. 2023BEG02011), the Ningxia Gut Homeostasis and Chronic Disease Prevention and Treatment Scientific and Technological Innovation Team, China (Grant No. 2022BSB03112), the Ningxia Natural Science Foundation (Grant No. 2026AAC030205), the Program of Ningxia Science and Technology Leading Talent, China (Grant No. 2023GKLRLX17).

We would like to thank our lab 120 family for their help and support in the research. We also gratefully acknowledge Wenke Shen, Jian Liu, Tian Ma, Ke Li, Jinyu Li, and Huifang Li for their generous assistance and technical support in the experimental work.

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: NCBI, accession number PRJNA624034.

AUTHOR CONTRIBUTIONS

Conception or design: X.Z., M.L., S.L., T.W., H.W. Acquisition, analysis, or interpretation of data: X.Z., M.L., S.L., Y.L., J.M., Y.L., F.Z., J.Z., H.W. Drafting the work or revising: X.Z., H.W. Final approval of the manuscript: T.W., H.W.

Supplementary Material

Supplemental Fig. S1.

Modulations of secoisolariciresinol diglucoside (SDG) administration on the proportion of peritoneal macrophages (Mψs) in polycystic ovary syndrome rats. (A) Representative flow cytometry scatter plot of spleen cells. (B) The proportion of CD45+CD68+ cells. (C) The proportion of CD45+CD68+CD86+ cells. Data are expressed as mean±standard deviation. CON, control; MOD, model; SSCA, side scatter area; PC, phycoerythrin-cyanine; APC, allophycocyanin; FITC, fluorescein isothiocyanate. aP<0.05; bP<0.01.

Supplemental Fig. S2.

Alpha diversity and beta diversity analysis of the fecal samples. (A) Venn diagram. (B) Rank-abundance curves. (C) Principal coordinates analysis (PCoA), beta diversity was on unweighted unique fraction. (D) Non-metric multidimensional scaling (NMDS) analysis, beta diversity was on weighted distance matrices. SDG, secoisolariciresinol diglucoside; CON, control; MOD, model; PC, principal coordinate; MDS, multidimensional scaling.

Supplemental Fig. S3.

Alpha diversity and beta diversity analysis of the vaginal secretion samples. (A) Venn diagram. (B) Rank-abundance curves. (C) Principal coordinates analysis (PCoA), beta diversity was on unweighted unique fraction. (D) Non-metric multidimensional scaling (NMDS) analysis, beta diversity was on weighted distance matrices. SDG, secoisolariciresinol diglucoside; CON, control; MOD, model; PC, principal coordinate; MDS, multidimensional scaling.

Supplemental Fig. S4.

Abundance plot of key metabolites. Metabolite changed trends were compared between control (CON) group and model (MOD) group samples. (A) Tryptamine. (B) Hyaluronic acid. (C) Cytidine. (D) L-Arginine. (E) Homovanillic acid. (F) Robustic acid. (G) Trehalose. (H) L-Phenylalanine. (I) 3-(3-Hydroxyphenyl) propanoic acid. (J) L-Gulonolactone. (K) Pro–Lys. (L) Sinapic acid. (M) 1-Methylnicotinamide. (N) L-Homoserine. (O) L-Acetylcarnitine. (P) Xanthurenic acid. (Q) Pyridoxal. (R) Indole-3-carboxylic acid. (S) L-Tryptophan. (T) L-Isoleucine. (U) 4-Acetamidobutanoic acid. (V) Papaverine. (W) L-Alanine. Data are expressed as mean±standard deviation. aP<0.01; bP<0.001.

Supplemental Fig. S5.

Abundance plot of key metabolites. Metabolite changed trends were compared between model (MOD) group and MOD+secoisolariciresinol diglucoside (SDG) group samples. (A) 4-Acetamidobutanoic acid. (B) Diethylthiophosphate. (C) Indole-3-car-boxylic acid. (D) L-Isoleucine. (E) L-Tryptophan. (F) Papaverine. (G) Pomiferin. (H) Cytidine. (I) Hyaluronic acid. (J) R-1-Methanandamide phosphate. (K) trans-Cinnamic acid. (L) Trehalose. (M) Tryptamine. Data are expressed as mean±standard deviation. aP<0.01; bP<0.001.

REFERENCES

  • 1. Stener-Victorin E, Teede H, Norman RJ, Legro R, Goodarzi MO, Dokras A, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024;10:27. doi: 10.1038/s41572-024-00511-3. [DOI] [PubMed] [Google Scholar]
  • 2. Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10:668–80. doi: 10.1016/S2213-8587(22)00163-2. [DOI] [PubMed] [Google Scholar]
  • 3. Parker J, O’Brien C, Hawrelak J, Gersh FL. Polycystic ovary syndrome: an evolutionary adaptation to lifestyle and the environment. Int J Environ Res Public Health. 2022;19:1336. doi: 10.3390/ijerph19031336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Kourtidou C, Tziomalos K. Pharmacological management of obesity in patients with polycystic ovary syndrome. Biomedicines. 2023;11:496. doi: 10.3390/biomedicines11020496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Liao B, Qi X, Yun C, Qiao J, Pang Y. Effects of androgen excess-related metabolic disturbances on granulosa cell function and follicular development. Front Endocrinol (Lausanne) 2022;13:815968. doi: 10.3389/fendo.2022.815968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Zhang Y, Weng Y, Wang D, Wang R, Wang L, Zhou J, et al. Curcumin in combination with aerobic exercise improves follicular dysfunction via inhibition of the hyperandrogen-induced IRE1α/XBP1 endoplasmic reticulum stress pathway in PCOS-like rats. Oxid Med Cell Longev. 2021;2021:7382900. doi: 10.1155/2021/7382900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22:3789. doi: 10.3390/ijms22073789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Mizgier M, Wieckowska B, Formanowicz D, Lombardi G, Brozek A, Nowicki M, et al. Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls: a pilot study. Sci Rep. 2024;14:3525. doi: 10.1038/s41598-024-54100-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Yang Z, Wu S, He S, Han L, Zhou M, Yang J, et al. LncRNA AOC4P impacts the differentiation of macrophages and T-lymphocyte by regulating the NF-κB pathways of KGN cells: potential pathogenesis of polycystic ovary syndrome. Am J Reprod Immunol. 2023;90:e13776. doi: 10.1111/aji.13776. [DOI] [PubMed] [Google Scholar]
  • 10. Wang J, Yin T, Liu S. Dysregulation of immune response in PCOS organ system. Front Immunol. 2023;14:1169232. doi: 10.3389/fimmu.2023.1169232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Chen K, Geng H, Ye C, Liu J. Dysbiotic alteration in the fecal microbiota of patients with polycystic ovary syndrome. Microbiol Spectr. 2024;12 doi: 10.1128/spectrum.04291-23. e0429123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Li P, Shuai P, Shen S, Zheng H, Sun P, Zhang R, et al. Perturbations in gut microbiota composition in patients with polycystic ovary syndrome: a systematic review and meta-analysis. BMC Med. 2023;21:302. doi: 10.1186/s12916-023-02975-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Yang YL, Zhou WW, Wu S, Tang WL, Wang ZW, Zhou ZY, et al. Intestinal flora is a key factor in insulin resistance and contributes to the development of polycystic ovary syndrome. Endocrinology. 2021;162:bqab118.. doi: 10.1210/endocr/bqab118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Espinosa ME, Melo A, Leon M, Bautista-Valarezo E, Zambrano F, Uribe P, et al. Vaginal microbiota and proinflammatory status in patients with polycystic ovary syndrome: an exploratory study. J Clin Med. 2024;13:2278. doi: 10.3390/jcm13082278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Noreen S, Tufail T, UlAin HB, Awuchi CG. Pharmacological, nutraceutical, and nutritional properties of flaxseed (Linum usitatissimum): an insight into its functionality and disease mitigation. Food Sci Nutr. 2023;11:6820–9. doi: 10.1002/fsn3.3662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Guo Y, Yang X, Tse TJ, Purdy SK, Mustafa R, Shen J, et al. Hypocholesterolemic efficacy of secoisolariciresinol diglucoside and its polymer in rat. J Nat Prod. 2021;84:2845–50. doi: 10.1021/acs.jnatprod.1c00549. [DOI] [PubMed] [Google Scholar]
  • 17. Chen G, Chen Y, Hong J, Gao J, Xu Z. Secoisolariciresinol diglucoside regulates estrogen receptor expression to ameliorate OVX-induced osteoporosis. J Orthop Surg Res. 2023;18:792. doi: 10.1186/s13018-023-04284-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Kamal DA, Ibrahim SF, Ugusman A, Mokhtar MH. Kelulut honey ameliorates oestrus cycle, hormonal profiles, and oxidative stress in letrozole-induced polycystic ovary syndrome rats. Antioxidants (Basel) 2022;11:1879. doi: 10.3390/antiox11101879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Adolphe JL, Whiting SJ, Juurlink BH, Thorpe LU, Alcorn J. Health effects with consumption of the flax lignan secoisolariciresinol diglucoside. Br J Nutr. 2010;103:929–38. doi: 10.1017/S0007114509992753. [DOI] [PubMed] [Google Scholar]
  • 20. Dunning K, Safo AO. The ultimate Wright-Giemsa stain: 60 years in the making. Biotech Histochem. 2011;86:69–75. doi: 10.3109/10520295.2010.515496. [DOI] [PubMed] [Google Scholar]
  • 21. Cora MC, Kooistra L, Travlos G. Vaginal cytology of the laboratory rat and mouse: review and criteria for the staging of the estrous cycle using stained vaginal smears. Toxicol Pathol. 2015;43:776–93. doi: 10.1177/0192623315570339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Lai H, Jia X, Yu Q, Zhang C, Qiao J, Guan Y, et al. High-fat diet induces significant metabolic disorders in a mouse model of polycystic ovary syndrome. Biol Reprod. 2014;91:127. doi: 10.1095/biolreprod.114.120063. [DOI] [PubMed] [Google Scholar]
  • 23. Wang T, Sha L, Li Y, Zhu L, Wang Z, Li K, et al. Dietary α-linolenic acid-rich flaxseed oil exerts beneficial effects on polycystic ovary syndrome through sex steroid hormonesmicrobiota- inflammation axis in rats. Front Endocrinol (Lausanne) 2020;11:284. doi: 10.3389/fendo.2020.00284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Brink LR, Mercer KE, Piccolo BD, Chintapalli SV, Elolimy A, Bowlin AK, et al. Neonatal diet alters fecal microbiota and metabolome profiles at different ages in infants fed breast milk or formula. Am J Clin Nutr. 2020;111:1190–202. doi: 10.1093/ajcn/nqaa076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Pereira MP, Jones S, Costin JM. Association of polycystic ovarian syndrome (PCOS) with vaginal microbiome dysbiosis: a scoping review. Cureus. 2024;16:e62611. doi: 10.7759/cureus.62611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Koh A, Molinaro A, Stahlman M, Khan MT, Schmidt C, Manneras-Holm L, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell. 2018;175:947–61. doi: 10.1016/j.cell.2018.09.055. [DOI] [PubMed] [Google Scholar]
  • 27. Koh A, Manneras-Holm L, Yunn NO, Nilsson PM, Ryu SH, Molinaro A, et al. Microbial imidazole propionate affects responses to metformin through p38γ-dependent inhibitory AMPK phosphorylation. Cell Metab. 2020;32:643–53. doi: 10.1016/j.cmet.2020.07.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Kezimana P, Dmitriev AA, Kudryavtseva AV, Romanova EV, Melnikova NV. Secoisolariciresinol diglucoside of flaxseed and its metabolites: biosynthesis and potential for nutraceuticals. Front Genet. 2018;9:641. doi: 10.3389/fgene.2018.00641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Rizk FH, ElSaadany AA, Elshamy AM, Abd Ellatif RA, El-Guindy DM, Helal DS, et al. Ameliorating effects of adropin on letrozole-induced polycystic ovary syndrome via regulating steroidogenesis and the microbiota inflammatory axis in rats. J Physiol. 2024;602:3621–39. doi: 10.1113/JP285793. [DOI] [PubMed] [Google Scholar]
  • 30. Zhou Y, Lan H, Dong Z, Li W, Qian B, Zeng Z, et al. Rhamnocitrin attenuates ovarian fibrosis in rats with letrozole-induced experimental polycystic ovary syndrome. Oxid Med Cell Longev. 2022;2022:5558599. doi: 10.1155/2022/5558599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974;3:69–96. doi: 10.1111/j.1365-2265.1974.tb03298.x. [DOI] [PubMed] [Google Scholar]
  • 32. Helvaci N, Yildiz BO. Polycystic ovary syndrome as a metabolic disease. Nat Rev Endocrinol. 2025;21:230–44. doi: 10.1038/s41574-024-01057-w. [DOI] [PubMed] [Google Scholar]
  • 33. Pieczynska JM, Pruszynska-Oszmalek E, Kolodziejski PA, Lukomska A, Bajerska J. The role of a high-fat, high-fructose diet on letrozole-induced polycystic ovarian syndrome in prepubertal mice. Nutrients. 2022;14:2478. doi: 10.3390/nu14122478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Wu Y, Yang X, Hu Y, Hu X, Zhang Y, An T, et al. Moringa oleifera leaf supplementation relieves oxidative stress and regulates intestinal flora to ameliorate polycystic ovary syndrome in letrozole-induced rats. Food Sci Nutr. 2023;11:5137–56. doi: 10.1002/fsn3.3473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Wei L, Zhao C, Dong S, Yao S, Ji B, Zhao B, et al. Secoisolariciresinol diglucoside alleviates hepatic lipid metabolic misalignment involving the endoplasmic reticulum-mitochondrial axis. Food Funct. 2020;11:3952–63. doi: 10.1039/d0fo00124d. [DOI] [PubMed] [Google Scholar]
  • 36. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009;48:11–22. doi: 10.1093/rheumatology/ken395. [DOI] [PubMed] [Google Scholar]
  • 37. Chen M, Zhu R, Wu T, Zhao W. Amelioration of oxidative kidney damage in offspring by maternal trans-fatty acid exposure in mice by secoisolariciresinol diglucoside. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023;48:967–78. doi: 10.11817/j.issn.1672-7347.2023.220524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Orisaka M, Mizutani T, Miyazaki Y, Shirafuji A, Tamamura C, Fujita M, et al. Chronic low-grade inflammation and ovarian dysfunction in women with polycystic ovarian syndrome, endometriosis, and aging. Front Endocrinol (Lausanne) 2023;14:1324429. doi: 10.3389/fendo.2023.1324429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Li H, Meng Y, He S, Tan X, Zhang Y, Zhang X, et al. Macrophages, chronic inflammation, and insulin resistance. Cells. 2022;11:3001. doi: 10.3390/cells11193001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Atrooz F, Salim S. Sleep deprivation, oxidative stress and inflammation. Adv Protein Chem Struct Biol. 2020;119:309–36. doi: 10.1016/bs.apcsb.2019.03.001. [DOI] [PubMed] [Google Scholar]
  • 41. Zhang L, Lan Y, Wang Y, Yang Y, Han W, Li J, et al. Secoisolariciresinol diglucoside ameliorates high fat diet-induced colon inflammation and regulates gut microbiota in mice. Food Funct. 2022;13:3009–22. doi: 10.1039/d1fo04037e. [DOI] [PubMed] [Google Scholar]
  • 42. Wang Z, Chen T, Yang C, Bao T, Yang X, He F, et al. Secoisolariciresinol diglucoside suppresses Dextran sulfate sodium salt-induced colitis through inhibiting NLRP1 inflammasome. Int Immunopharmacol. 2020;78:105931. doi: 10.1016/j.intimp.2019.105931. [DOI] [PubMed] [Google Scholar]
  • 43. Zhang Z, Wang S, Liu X, Yang Y, Zhang Y, Li B, et al. Secoisolariciresinol diglucoside ameliorates osteoarthritis via nuclear factor-erythroid 2-related factor-2/nuclear factor kappa B pathway: in vitro and in vivo experiments. Biomed Pharmacother. 2023;164:114964. doi: 10.1016/j.biopha.2023.114964. [DOI] [PubMed] [Google Scholar]
  • 44. Zhou M, Yu J, Li X, Ruan Z, Yu S. Role of the gut microbiota and innate immunity in polycystic ovary syndrome: current updates and future prospects. J Cell Mol Med. 2024;28:e18258. doi: 10.1111/jcmm.18258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Wu J, Wang K, Qi X, Zhou S, Zhao S, Lu M, et al. The intestinal fungus Aspergillus tubingensis promotes polycystic ovary syndrome through a secondary metabolite. Cell Host Microbe. 2025;33:119–36. doi: 10.1016/j.chom.2024.12.006. [DOI] [PubMed] [Google Scholar]
  • 46. Guan R, Ma N, Liu G, Wu Q, Su S, Wang J, et al. Ethanol extract of propolis regulates type 2 diabetes in mice via metabolism and gut microbiota. J Ethnopharmacol. 2023;310:116385. doi: 10.1016/j.jep.2023.116385. [DOI] [PubMed] [Google Scholar]
  • 47. Li H, Shen M, Chen X, Wu Y, Zeng F, Xie J. Dietary flaxseed oil and its blended oil alleviate high-fat diet-induced obesity in mice by improving lipid metabolism and regulating gut microbiota. Foods. 2025;14:1877. doi: 10.3390/foods14111877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Cristofori F, Dargenio VN, Dargenio C, Miniello VL, Barone M, Francavilla R. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. Front Immunol. 2021;12:578386. doi: 10.3389/fimmu.2021.578386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Jin C, Qin L, Liu Z, Li X, Gao X, Cao Y, et al. Comparative analysis of the vaginal microbiome of healthy and polycystic ovary syndrome women: a large cross-sectional study. Reprod Biomed Online. 2023;46:1005–16. doi: 10.1016/j.rbmo.2023.02.002. [DOI] [PubMed] [Google Scholar]
  • 50. Xu H, Zhang S, Zhang B, Jiang N, Xu Y, Chen X, et al. Vaginal colonization of Lactobacilli: mechanism and function. Microb Pathog. 2025;198:107141. doi: 10.1016/j.micpath.2024.107141. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Fig. S1.

Modulations of secoisolariciresinol diglucoside (SDG) administration on the proportion of peritoneal macrophages (Mψs) in polycystic ovary syndrome rats. (A) Representative flow cytometry scatter plot of spleen cells. (B) The proportion of CD45+CD68+ cells. (C) The proportion of CD45+CD68+CD86+ cells. Data are expressed as mean±standard deviation. CON, control; MOD, model; SSCA, side scatter area; PC, phycoerythrin-cyanine; APC, allophycocyanin; FITC, fluorescein isothiocyanate. aP<0.05; bP<0.01.

Supplemental Fig. S2.

Alpha diversity and beta diversity analysis of the fecal samples. (A) Venn diagram. (B) Rank-abundance curves. (C) Principal coordinates analysis (PCoA), beta diversity was on unweighted unique fraction. (D) Non-metric multidimensional scaling (NMDS) analysis, beta diversity was on weighted distance matrices. SDG, secoisolariciresinol diglucoside; CON, control; MOD, model; PC, principal coordinate; MDS, multidimensional scaling.

Supplemental Fig. S3.

Alpha diversity and beta diversity analysis of the vaginal secretion samples. (A) Venn diagram. (B) Rank-abundance curves. (C) Principal coordinates analysis (PCoA), beta diversity was on unweighted unique fraction. (D) Non-metric multidimensional scaling (NMDS) analysis, beta diversity was on weighted distance matrices. SDG, secoisolariciresinol diglucoside; CON, control; MOD, model; PC, principal coordinate; MDS, multidimensional scaling.

Supplemental Fig. S4.

Abundance plot of key metabolites. Metabolite changed trends were compared between control (CON) group and model (MOD) group samples. (A) Tryptamine. (B) Hyaluronic acid. (C) Cytidine. (D) L-Arginine. (E) Homovanillic acid. (F) Robustic acid. (G) Trehalose. (H) L-Phenylalanine. (I) 3-(3-Hydroxyphenyl) propanoic acid. (J) L-Gulonolactone. (K) Pro–Lys. (L) Sinapic acid. (M) 1-Methylnicotinamide. (N) L-Homoserine. (O) L-Acetylcarnitine. (P) Xanthurenic acid. (Q) Pyridoxal. (R) Indole-3-carboxylic acid. (S) L-Tryptophan. (T) L-Isoleucine. (U) 4-Acetamidobutanoic acid. (V) Papaverine. (W) L-Alanine. Data are expressed as mean±standard deviation. aP<0.01; bP<0.001.

Supplemental Fig. S5.

Abundance plot of key metabolites. Metabolite changed trends were compared between model (MOD) group and MOD+secoisolariciresinol diglucoside (SDG) group samples. (A) 4-Acetamidobutanoic acid. (B) Diethylthiophosphate. (C) Indole-3-car-boxylic acid. (D) L-Isoleucine. (E) L-Tryptophan. (F) Papaverine. (G) Pomiferin. (H) Cytidine. (I) Hyaluronic acid. (J) R-1-Methanandamide phosphate. (K) trans-Cinnamic acid. (L) Trehalose. (M) Tryptamine. Data are expressed as mean±standard deviation. aP<0.01; bP<0.001.


Articles from Endocrinology and Metabolism are provided here courtesy of Korean Endocrinology Society

RESOURCES